Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2026 Mar 10;21(3):e0315818.
doi: 10.1371/journal.pone.0315818. eCollection 2026.

Prevalence of medication-related problems and its predictors among cancer patients in Ethiopia: A systematic review and meta-analysis

Malede Berihun Yismaw  1 , Chernet Tafere  1 , Bereket Bahiru Tefera  1 , Adane Yehualaw  1 , Desalegn Getnet Demsie  1 , Kebede Feyisa  1 , Zenaw Debasu Addisu  1 , Zegaye Agmassie  1 , Endalamaw Aschale  1 , Tirsit Ketsela Zeleke  2 , Rahel Belete Abebe  3 , Eyob Ketema Bogale  4 , Belayneh Kefale  1   5
Affiliations
Meta-Analysis

Prevalence of medication-related problems and its predictors among cancer patients in Ethiopia: A systematic review and meta-analysis

Malede Berihun Yismaw et al. PLoS One. .

Abstract

Background: Preventable medication-related problems intensify the risk associated with cancer care and no data was available to represent the burden of medication-related problems among cancer patients in Ethiopia. Hence, this study was aimed to estimate the pooled prevalence of medication-related problems and identify its predictors among cancer patients treated in Ethiopia.

Methods: A systematic review and meta-analysis of studies retrieved from databases (Medline, EMBASE, Scopus, Cumulative Index to the Nursing and Allied Literature (CINAHL), Cochrane Library and Google Scholar) for relevant literature published before April, 2024 was made. We included observational studies conducted in Ethiopia that reported on the types, frequency, or risk factors of medication-related problems in cancer patients. Reviews, case reports, qualitative studies, and studies lacking relevant outcomes were excluded. The Newcastle-Ottawa quality assessment scale was used for quality assessment and the Egger's regression test and the Galbraith plot were used to evaluate publication bias. The national prevalence of medication-related problems was estimated using a random-effects model meta-analysis. Moreover, subgroup analysis and meta-regression analyses were done to explore the reasons of statistical heterogeneity. The study protocol has been registered with PROSPERO under number CRD42024505218.

Results: A total of 15 studies comprising of 3084 cancer patients were included in this study. The adjusted pooled prevalence of medication-related problems of cancer patients who experienced at least one medication-related problem was 48% [0.48 (95% CI: 0.39-0.57; I2 = 96%; p < 0.01)]. The study also revealed the pooled prevalence of non-adherence among the included studies to be 42% [0.42 (95% CI: 0.27-0.57; I2 = 97%; p < 0.01)]. The presence of comorbidities (AOR = 4.47, 95% CI: 3.26-5.69), complications (AOR = 5.78, 95% CI: 3.26-8.30) and polypharmacy (AOR = 3.75, 95% CI: 2.16-5.34) were found to be predictors of developing medication-related problems.

Conclusion: This review found a high pooled prevalence of medication-related problems among cancer patients in Ethiopia, with predictors including comorbidities, complications and polypharmacy. About two-fifths of patients were not fully adherent to their prescribed cancer treatments. These findings highlight the need for targeted interventions to improve medication safety and adherence, and underscore the importance of future research to identify effective strategies for reducing MRPs in oncology settings.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. PRISMA flow diagram describing the selection of studies for systematic review and meta-analysis of medication-related problems among cancer patients in Ethiopia.
Fig 2
Fig 2. Pooled prevalence of MRPs among cancer patients in Ethiopia.
Fig 3
Fig 3. Sub-group analysis of MRPs across study designs.
Fig 4
Fig 4. Pooled prevalence of non-adherence among studies reported the proportion of non-adherent individuals from the sample population.
Fig 5
Fig 5. Funnel plot showing event by the standard error of event for publication bias.
See this image and copyright information in PMC

References

    1. World Cancer Research Fund International. Cancer trends - Global cancer data by country. [cited 2024 Apr 3]. Available from: https://www.wcrf.org/cancer-trends/global-cancer-data-by-country/
    1. Sharma R, Aashima, Nanda M, Fronterre C, Sewagudde P, Ssentongo AE, et al. Mapping Cancer in Africa: A Comprehensive and Comparable Characterization of 34 Cancer Types Using Estimates From GLOBOCAN 2020. Front Public Health. 2022;10:839835. doi: 10.3389/fpubh.2022.839835 - DOI - PMC - PubMed
    1. International Agency for Research on Cancer, World Health Organization. Cancer fact sheets, Ethiopia 2022. GLOBOCAN. 2022. [cited 2024 Apr 3]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/231-ethio...
    1. National Cancer Institute. Types of Cancer Treatment. [cited 2024 Apr 3]. Available from: https://www.cancer.gov/about-cancer/treatment/types
    1. Wagland R, Richardson A, Armes J, Hankins M, Lennan E, Griffiths P. Treatment-related problems experienced by cancer patients undergoing chemotherapy: a scoping review. Eur J Cancer Care (Engl). 2015;24(5):605–17. doi: 10.1111/ecc.12246 - DOI - PubMed